<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609033</url>
  </required_header>
  <id_info>
    <org_study_id>17300477</org_study_id>
    <nct_id>NCT04609033</nct_id>
  </id_info>
  <brief_title>Implications of Different Analgesic Models on Inflammatory Markers After Laparoscopic Cholecystectomy</brief_title>
  <official_title>Implications of Different Analgesic Models on Inflammatory Markers After Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative abdominal and shoulder pain that are experienced in patients undergoing&#xD;
      laparoscopic cholecystectomy (LC) is significant. Although it is generally less sever than&#xD;
      post open cholecystectomy pain, it still causes an avoidable distress in the first 24 hours&#xD;
      postoperatively&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of pain after laparoscopy may be as high as 36 to 63 percent and is attributed&#xD;
      to the carbon dioxide gas (CO2) used to induce pneumo-peritoneum1.&#xD;
&#xD;
      The residual part of CO2 remains in the peritoneal cavity for several days after the&#xD;
      operation and causes stretching of the phrenic nerve endings, local hypothermia, and&#xD;
      diaphragmatic irritation by carbonic acid formation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2020</start_date>
  <completion_date type="Actual">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative level of ACTH hormone</measure>
    <time_frame>6 hours</time_frame>
    <description>a stress marker that increase with pain and surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VISUUEAL ANALOGE SCORE</measure>
    <time_frame>24 hours</time_frame>
    <description>to assess postoperative pain</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Perioperative Pain</condition>
  <arm_group>
    <arm_group_label>bupivacaine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivacaine + morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivacaine + morphine + ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>isotonic saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>instillation of local anaesthetic in the abdominal cavity at the end of the procedure</description>
    <arm_group_label>bupivacaine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotonic saline</intervention_name>
    <description>instillation of local anaesthetic in the abdominal cavity at the end of the procedure</description>
    <arm_group_label>isotonic saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine + morphine</intervention_name>
    <description>instillation of local anaesthetic + morphine sulfate in the abdominal cavity at the end of the procedure</description>
    <arm_group_label>bupivacaine + morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine + morphine + ketamine</intervention_name>
    <description>instillation of local anaesthetic + morphine sulfate + ketamine in the abdominal cavity at the end of the procedure</description>
    <arm_group_label>bupivacaine + morphine + ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for Laparoscopic cholecystectomy.&#xD;
&#xD;
          -  Age spectrum of 18 - 55 years&#xD;
&#xD;
          -  ASA I, II&#xD;
&#xD;
          -  Have no comorbid chronic medical diseases&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with co morbid medical diseases&#xD;
&#xD;
          -  Age outside the specified range&#xD;
&#xD;
          -  Acute inflammation of the gall bladder&#xD;
&#xD;
          -  Critically ill patient&#xD;
&#xD;
          -  Emergency operations&#xD;
&#xD;
          -  Patient refusal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut University Hospitals</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Esam Hamed</investigator_full_name>
    <investigator_title>consultant</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

